Actively Recruiting
Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation in Patients Undergoing General Anaesthesia - a Multicentre Randomised Controlled Trial -The ROCVIDEO Trial
Led by Nordsjaellands Hospital · Updated on 2025-12-10
2648
Participants Needed
2
Research Sites
1 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of two different drugs, remifentanil and rocuronium, on conditions during video laryngoscopy-assisted tracheal intubation in patients undergoing general anaesthesia. The study aims to compare the safety and intubation success between using a neuromuscular blocking agent (rocuronium) and an opioid (remifentanil) for muscle relaxation during intubation. This research is important because airway management complications remain a leading cause of anaesthesia-related problems, and newer techniques like video laryngoscopy have improved intubation ease but lack clear evidence on the best drug method to optimize conditions. Participants will receive either a bolus of remifentanil or rocuronium at the start of anaesthesia. For those under 70 years old, remifentanil is given as 4 micrograms per kilogram of ideal body weight, and for those 70 or older, 2 micrograms per kilogram. Rocuronium is administered as a 0.6 milligram per kilogram bolus at anaesthesia induction. The study uses a quadruple-masked randomized design and compares the two arms to assess their effects on intubation conditions using video laryngoscopy. During the study, researchers will monitor for intubation or anaesthesia-related adverse events within 24 hours, and the success of first-pass intubation two minutes after drug administration. Additional assessments include patient satisfaction after 24 hours, serious adverse events within seven days, and length of stay in the post-anaesthesia care unit up to 48 hours after surgery. The study is planned to start in November 2025 and continue until April 2027, involving adult patients undergoing general anaesthesia who meet specific eligibility criteria.
CONDITIONS
Brief Title
Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years
- Undergoing general anaesthesia requiring oro-tracheal intubation
- No indication for rapid sequence induction
- ASA physical status score of I to III
You will not qualify if you...
- Known allergies or contraindications to rocuronium or remifentanil
- Awake intubation
- Use of double-lumen endotracheal tube
- Oral, pharyngeal, or laryngeal surgery
- Surgical contraindication for neuromuscular blocking agents
- Pregnancy or breastfeeding
- Unable to understand Danish or give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single administration during general anaesthesia
Participants receive a bolus of either remifentanil or rocuronium at anaesthesia induction to facilitate video laryngoscopy-assisted tracheal intubation.
1 treatment visit (in-person)
Duration - Up to 7 days
Participants are monitored for adverse events, patient satisfaction, and length of stay in the post-anaesthesia care unit for up to 7 days after drug administration.
Multiple visits during the first 48 hours and follow-up contacts up to 7 days
Trial Site Locations
Total: 2 locations
1
Department of Anesthesiology, NOH, Rigshospitalet
Copenhagen, Denmark, 2100
Actively Recruiting
2
Department of Anesthesiology, North Zeeland Hospital
Hillerød, Denmark, 3400
Actively Recruiting
Research Team
A
Anders K Nørskov, PhD
L
Lars H Lundstrøm, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here